New antibody BNT351 enters first human trial for HIV
NCT ID NCT07392372
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tests a new antibody called BNT351 in 67 adults, both with and without HIV. The goal is to check safety, how long the antibody stays in the blood, and whether it can lower HIV levels in people with the virus. It is a first step toward possibly controlling HIV with fewer medications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BNT351 (a broadly neutralizing antibody)
- What this could lead to
- If successful, this could point toward a new way to control HIV without daily pills, using periodic antibody infusions or injections.
- What could go wrong
- This is a very early Phase 1 trial with only 67 participants, so safety and effectiveness are not yet proven. The antibody may not lower virus levels enough or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV -1 INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CRS Mannheim
ACTIVE_NOT_RECRUITINGMannheim, 68167, Germany
-
Columbia University
NOT_YET_RECRUITINGNew York, New York, 10032, United States
-
Cook County Health
NOT_YET_RECRUITINGChicago, Illinois, 60612, United States
-
Johns Hopkins
RECRUITINGBaltimore, Maryland, 21205-1832, United States
-
UK Köln
RECRUITINGCologne, 50937, Germany
-
Washington University
NOT_YET_RECRUITINGSt Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking HIV's genetic fingerprints reveal where the epidemic is heading?
- Can a new drug, GS-0415, help keep HIV in check? a First-in-Human trial aims to find out
- Could a shot replace daily HIV pills? new trial tests injectable combo
- Long-acting HIV shot studied in patients with severe kidney problems
- RNA vaccine aims to control HIV without daily pills
- Herbal formula may help HIV patients whose immune systems Don't fully recover